Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01500096 · ClinicalTrials.gov registry record · Phase 2
American Ginseng to Improve HIV-Associated Fatigue: A Randomized, Placebo-Controlled, Parallel Design, Multiple-Dose Clinical Trial
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 96
- Enrollment target
NCT01500096: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT01500096 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 96 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (28% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01500096, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 96 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether American ginseng is effective in the treatment of HIV-associated fatigue.
Primary Outcome
Change in FSS score from baseline to Week 4. The change in fatigue as measured by the FSS (Week 4 minus Baseline) using the Wilcoxon test. The FSS is a scale score ranging from 1 to 63 with higher scores indicative of more fatigue. A negative number indicates a decline in the FSS scale. Participants with FSS data at both times points were assessed.
Interventions
- DRUG American ginseng
- DIETARY_SUPPLEMENT Placebo for American ginseng
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2013-02 |
| Est. Completion | 2016-09 |
| Phase | Phase 2 |
What the finished NCT01500096 record still lists
NCT01500096 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (28% lower).
The record links to 0 conditions, and to 2 interventions - of which American ginseng is the first listed.
NCT01500096 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01500096 about?
NCT01500096 is a clinical study titled "American Ginseng to Improve HIV-Associated Fatigue: A Randomized, Placebo-Controlled, Parallel Design, Multiple-Dose Clinical Trial". The purpose of this study is to determine whether American ginseng is effective in the treatment of HIV-associated fatigue.
What is the current status of trial NCT01500096?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2013-02. Estimated completion is 2016-09.
What interventions are being tested in trial NCT01500096?
The interventions under investigation include: American ginseng (DRUG), Placebo for American ginseng (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01500096?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01500096's enrollment target sits among peer trials
96 747th of 2000 higher than 1,242 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia